Related Experiment Videos
[Pharmacokinetic and clinical studies on sulbactam/ampicillin in the pediatric field]
Insights
Sulbactam/ampicillin (SBT/ABPC) demonstrated high efficacy (96%) in treating pediatric infections, including bronchopneumonia and urinary tract infections. This antibiotic combination proved safe and well-tolerated in children.
Area of Science:
- Pediatric Infectious Diseases
- Pharmacokinetics
- Antimicrobial Therapy
Background:
- Sulbactam/ampicillin (SBT/ABPC) is a novel antibiotic combination.
- Evaluating its safety and efficacy in pediatric patients is crucial.
Observation:
- Pharmacokinetic parameters including T 1/2 (beta) and urinary excretion rates were analyzed.
- Clinical efficacy was assessed across various pediatric infections.
- Adverse events were monitored for safety evaluation.
Findings:
- SBT/ABPC showed a 96% efficacy rate in treating pediatric infections like bronchopneumonia, bronchitis, and UTIs.
- Mean T 1/2 (beta) values were 0.94 hr for SBT and 0.86 hr for ABPC.
- Transient adverse events were observed in a small percentage of patients, indicating a favorable safety profile.
Implications:
- SBT/ABPC is a safe and effective treatment option for pediatric infections.
- The drug's pharmacokinetic profile supports its clinical utility.
- Further research may explore broader applications in pediatric infectious disease management.
Abstract:
The new antibiotic, sulbactam/ampicillin (SBT/ABPC) was administered to 25 children. The results obtained are summarized as follows. 1. In 5 cases of children administered with SBT/ABPC (30 mg/kg) by intravenous drip infusion for 30 minutes, the mean values of T 1/2 (beta) were 0.94 hour (SBT) and 0.86 hour (ABPC) and the mean 6.5 hour urinary excretion rates were 64.2% and 42.9%, respectively. 2. The antibiotic was administered to a total of 25 patients with bronchopneumonia, pneumonia, bronchitis, cervical lymphadenitis, tonsillitis, streptococcal infection, urinary tract infection, felon, periappendicular abscess, sepsis or purulent meningitis. Response to the treatment were excellent in 17 cases, good in 7, fair in 1, and poor in none. The efficacy rate was 96%. From our results, this drug appears to be particularly effective against bronchopneumonia, bronchitis and urinary tract infection. 3. Eruption occurred in 1 of 25 patients and elevation of eosinophil, GOT/GPT, platelet in 3 and descent of WBC in 1 were observed, but these were transient. These results showed that SBT/ABPC is a drug which can be safely used in the pediatric field as well as for adults.